Selected article for: "cross sectional study and positive case"
Author: Wang, Song-mi; Tao, Fang; Hou, Yan; Zhang, Ai; Xiong, Hao; Sun, Jun-jie; Luo, Xiao-ping; Hao, Yan; Li, Jian-xin; Hu, Qun; Liu, Ai-guo
Title: Screening of SARS-CoV-2 in 299 Hospitalized Children with Hemato-oncological Diseases: A Multicenter Survey in Hubei, China
  • Cord-id: t3yv5y7h
  • Document date: 2020_8_7
    • ID: t3yv5y7h
    Snippet: The SARS-CoV-2 infection status of hospitalized children was surveyed in the department of pediatric hematology and oncology in three different hospitals of epidemic areas in Hubei, China. A cross-sectional study was performed to investigate the clinical characteristics, lung CT scan, SARS-CoV-2 nucleic acid test and serum antibodies of hospitalized children with hemato-oncological diseases from January 23 to April 24, 2020. 299 children were enrolled in this study, including 176 males (58.9%) a
    Document: The SARS-CoV-2 infection status of hospitalized children was surveyed in the department of pediatric hematology and oncology in three different hospitals of epidemic areas in Hubei, China. A cross-sectional study was performed to investigate the clinical characteristics, lung CT scan, SARS-CoV-2 nucleic acid test and serum antibodies of hospitalized children with hemato-oncological diseases from January 23 to April 24, 2020. 299 children were enrolled in this study, including 176 males (58.9%) and 123 females (41.1%), aged from 2 months to 16 years. 255 cases (85.3%) received chemotherapy or other immunosuppressive therapies, and there were 44 cases (14.7%) of other benign diseases. Nucleic acid test was performed on 258 children (86.3%) and one case was positive. 163 cases (54.5%) were tested for serum antibodies, and all of them were negative. Lung CT scan was performed on 247 children (82.6%), and 107 of them showed infectious changes. Only one case (0.33%) of COVID-19 was diagnosed in the group. The prevalence rate of COVID-19 in enrolled children with hemato-oncological diseases in Hubei was 0.33%. Immunosuppressed patients are not prone to produce related antibodies. Comprehensive protective measures and ward management can reduce the risk of SARS-CoV-2 infection in the group patients.

    Search related documents:
    Co phrase search for related documents
    • abnormal imaging and acute lymphoblastic leukemia: 1
    • abnormal imaging and acute severe pneumonia: 1
    • abnormal imaging and lung imaging: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • abnormal imaging and lymphoblastic leukemia: 1
    • abnormal imaging and lymphocyte count: 1, 2, 3, 4
    • abnormal lung imaging and lung imaging: 1, 2, 3, 4, 5, 6, 7, 8
    • acid detection and acute severe pneumonia: 1, 2
    • acid detection and lung imaging: 1, 2
    • acid detection and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute heart failure and lung imaging: 1, 2
    • acute heart failure and lung imaging lesion: 1
    • acute heart failure and lymphocyte count: 1, 2, 3, 4, 5, 6
    • acute lymphoblastic leukemia and lymphoblastic leukemia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
    • acute lymphoblastic leukemia and lymphocyte count: 1
    • acute lymphoblastic leukemia diagnose and lymphoblastic leukemia: 1
    • acute severe pneumonia and lung ct examination: 1
    • acute severe pneumonia and lung imaging: 1, 2, 3, 4
    • acute severe pneumonia and lymphoblastic leukemia: 1
    • acute severe pneumonia and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11